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Abstract
Background Around 30% of all stage II colon cancer
patients will relapse and die of their disease. At present
no objective parameters to identify high-risk stage II colon
cancer patients, who will benefit from adjuvant chemother-
apy, have been established. With traditional histopatholog-
ical features definition of high-risk stage II colon cancer
patients is inaccurate. Therefore more objective and robust
markers for prediction of relapse are needed. DNA copy
number aberrations have proven to be robust prognostic
markers, but have not yet been investigated for this specific
group of patients. The aim of the present study was to
identify chromosomal aberrations that can predict relapse of
tumor in patients with stage II colon cancer.
Materials and methods DNA was isolated from 40 formal-
dehyde fixed paraffin embedded stage II colon cancer
samples with extensive clinicopathological data. Samples
were hybridized using Comparative Genomic Hybridization
(CGH) arrays to determine DNA copy number changes and
microsatellite stability was determined by PCR. To analyze
differences between stage II colon cancer patients with and
without relapse of tumor a Wilcoxon rank-sum test was
implemented with multiple testing correction.
Results Stage II colon cancers of patients who had relapse of
disease showed significantly more losses on chromosomes 4,
5, 15q, 17q and 18q. In the microsatellite stable (MSS)
subgroup (n=28), only loss of chromosome 4q22.1-4q35.2
was significantly associated with disease relapse (P<0.05,
FDR<0.15). No differences in clinicopathological character-
istics between patients with and without relapse were
observed.
Conclusion In the present series of MSS stage II colon
cancer patients losses on 4q22.1-4q35.2 were associated
with worse outcome and these genomic alterations may aid
in selecting patients for adjuvant therapy.
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Worldwide, colorectal cancer (CRC) is the third most
common cancer affecting more than 940,000 patients
annually. Nearly 500,000 patients die from the consequen-
ces of CRC each year (www.who.int)[ 43]. In the Nether-
lands in 2006, 11231 patients were diagnosed with CRC
and 4709 CRC related deaths occurred [40]. The incidence
of CRC is relatively high in the western world and steadily
increases each year [40]. Two thirds of all CRCs occur in
the colon and one third is located in the rectum. Patients
with colon tumors are treated differently and have a
different prognosis compared to rectal cancer patients.
Staging is traditionally based on pathologist’s evaluation
of tumor extent, lymph nodes and distant metastasis, all
included in the TNM classification [34] and therapeutic
decisions are based on this system. Upon resection of the
primary tumor, some 40% of all colon cancers appear to be
stage II (TNM/UICC) [34]. Of patients with stage II colon
cancer 20–30% will relapse, i.e. develop distant metastasis,
and these patients will die of their disease. Five-year
survival rates for stage II colon vary between 50% and
90%. Patients with stage III colon cancer will face relapse
of tumor during follow-up in 60% of cases and chemotherapy
can reduce recurrence rates with 40–50% [45]. Although
postoperative chemotherapy is standard for stage III colon
cancer it is not for stage II colon cancer [5, 14]. Nevertheless,
it has been shown that subgroups of patients with stage II
colon cancer can benefit from adjuvant chemotherapy [24].
In fact, high risk stage II colorectal cancer patients have a
worse prognosis than single node positive stage III colorectal
cancer patients [28]. Better prediction of relapse as an
indication for the need of adjuvant chemotherapy is thus
required for stage II colorectal cancer [5]. Histopathological
and clinical variables are most frequently used for identifying
high risk stage II colon cancers. Peritoneal involvement,
extramural vascular invasion, tumor perforation, male gender,
bowelobstruction,numberofnodesharvestedandpresenceof
lymph node micro metastasis have all been identified as
negative prognostic factors in stage II colon cancer [16, 22,
30]. Notwithstanding this extensive body of work, these
histopathological factors have not yet provided an estab-
lished basis for accurately identifying patients at high risk for
relapse in a clinical setting. Molecular markers can help to
select stage II colon cancer patients with worse prognosis.
Gene expression profiles have been able to identify stage II
colon cancer patients at high risk for relapse [4, 15].
However, RNA is an instable molecule and its expression
subject to environmental and circadian rhythms. In contrast,
DNA is more stable and can be obtained for copy number
analysis from formalin fixed paraffin embedded (FFPE)
material which is frequently the only material available in
routine clinical practice. DNA copy number aberrations are a
hallmark of cancer. These chromosomal aberrations are less
frequent in micro satellite instable (MSI) tumors compared to
micro satellite stable (MSS) tumors. The latter group is also
referred to Chromosomal Instable (CIN) and accounts for
85% of all colorectal tumors. MSS CRCs have a worse
outcome than MSI CRCs [41].
In CRC, chromosomal aberrations, important for tumor
progression and prognosis, have been studied [12, 18–20,
23, 27, 29, 32], but to which extent specific chromosomal
changes have prognostic value specifically in stage II colon
cancer patients has only been analyzed in limited detail.
Therefore, the present study analyzed genome wide DNA
copy number changes using high resolution oligonucleotide
based array CGH for identifying chromosomal aberrations
that may be used as prognostic markers for patients with
stage II colon cancer.
2 Materials and methods
2.1 Patient and sample selection
Forty patients operated between 1990 and 2000 for stage II
colon cancer (pT3 or pT4, pN0, pM0, R0 TNM classifica-
tion, fifth edition [34]) were selected for this study, 16 with
and 24 without relapse. Seventeen patients underwent
resection of their primary tumor at the John Goligher
Colorectal Unit, Leeds General Infirmary (UK) and 23
patients at the Zaans Medical Centre (NL). Medical records
of all patients were reviewed retrospectively to obtain
clinical data, patient characteristics and follow-up data.
None of the patients received postoperative chemotherapy
or radiotherapy. Tumor relapse was defined as the occur-
rence of distant metastasis, confirmed by ultrasound, CT
scan and/or histology within 36 months. Haematoxylin &
eosin (H&E) stained sections were reviewed by a pathologist
for TNM tumor stage [34], differentiation grade, number of
nodes assessed tumor perforation, extramural vascular
invasion (EMVI) and peritoneal involvement. All samples
were used in compliance with the respective institutional
ethical regulations for surplus material and use of material
from Leeds General Infirmary (UK) was approved by the
Leeds (West) research ethics committee, unique identifier
CA02/014.
2.2 DNA isolation from formalin-fixed
and paraffin-embedded (FFPE) tissue blocks
DNA was isolated from FFPE colon cancer tissue of 40
samples. Corresponding normal mucosa DNA was isolated
from 37 of the samples as a reference and was obtained
from the resection margins or at least 1 cm distance from
the tumor. For 3 cases no normal mucosa was available and
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eighteen healthy males was used. For each tumor an area
containing at least 70% of tumor cells was marked on the
slides. Of the FFPE blocks 4 to 6 10 μm sections were cut,
deparaffinized and macro dissected. Isolation of DNA was
performed as previously described [42], including incuba-
tion with sodium thiocyanate (1 M, CNNaS), proteinase K
treatment and purification using a column based method
(QIAamp microkit; Qiagen, Hilden, Germany).
2.3 Microsatellite stability
All samples were analyzed for Microsatellite instability
(MSI) using MSI Analysis System, Version 1.1 according
to manufacturer’s instructions (Promega, Madison, USA).
This PCR based assay is using 5 mononucleotide markers
to determined MSI status. PCR product were separated by
capillary electrophoresis using ABI 3130 DNA sequencer
and output data were analyzed using the accompanying
package GeneScan 3100 (Applied Biosystems, Foster City.
CA, USA). Tumors were classified as MSI when instability
of two or more markers was seen. When a single or no
instable markers were seen, tumors were considered as
micro satellite stable (MSS).
2.4 Chromosomal copy number analysis by array
comparative genomic hybridization (array CGH)
Labeling and hybridization was done as previously described
[6]. Briefly, 500 ng of genomic DNA of tumor and reference
was labeled with either Cyanine 3-UTP (Cy3) or Cyanine 5-
UTP (Cy5) nucleotide mixture, respectively, according to
manufacturer’s instructions (CGH labeling Kit for Oligo
Arrays, Enzo Life Sciences, Farmingdale, NY, USA) and
purified using the QIAquick PCR Purification Kit (Qiagen,
Westburg, Leusden, NL). Labeled tumor and (matched)
reference DNAs were mixed prior to hybridization onto
Agilent 4x44K oligonucleotide arrays (Agilent Technologies,
Palo Alto, USA). Each slide consists of 4 arrays, each
containing 45220 in-situ synthesized 60-mer oligonucleo-
tides representing 42494 unique biological features distrib-
uted over the genome. Immediately after hybridization the
slides were scanned using microarray scanner G2505B
(Agilent technologies, Palo Alto, USA) and image analysis
was performed using feature extraction software (version 9.1,
Agilent Technologies, Palo Alto, USA). The Agilent CGH-
v4_91 protocol was applied using default settings. Oligonu-
cleotides were mapped according to the human genome
build NCBI 36 (May 2006). Of both Cy3 and Cy5 channels,
local background was subtracted from the median intensities.
The log2 tumor to normal intensity ratio was calculated for
each spot and normalized against the median of the ratios of
all autosomes.
2.5 Statistical analysis of genomic profiles
Analysis of array CGH data was done in the statistical
computing language R, version 2.6.1 (http://www.r-project.
org). Chromosomal copy number losses and gains were
identified using the package CGHcall [37] with cellularity
s e tt o0 . 7a n dm e d i a nn o r m a l i z a t i o n .T or e d u c et h e
dimension of the array CGH data set without loss of
information, regions were defined as previously described
[39].
To calculate significance of DNA copy number differences
between patients who did and did not relapse, a Wilcoxon-
Mann-Whitney two sample test was used, implemented in the
software package CGHmultiarray, that provides multiple
comparison correction [38]. Differences were analyzed for
all patients and for MSS colon cancer patients separately.
P-values of <0.05 and false discovery rates, i.e. the expected
proportion of false positives among the DNA copy numbers
claimed to be correlated with outcome, of <0.15 were
considered to be statistical significant [13].
Statistical analysis of associations with histopathological
and clinical variables was performed using SPSS software
(SPPS for Windows, version 15.0, SPSS Inc.Chicago, IL,
USA). Mann-Whitney U test and Chi-square test were used
for analyzing differences in continuous or categorical
variables, respectively. For correlations with overall survival
(OS) and Disease free survival (DFS) univariate survival
analysis with log rank statistics was used and Kaplan-Meier
curves were constructed. To determine independent effects
of clinical variables and DNA copy number changes,
multivariate Cox proportional hazard analysis was performed.
OS and DFS were defined as time from surgery to date of
death due to all causes or to date of first evidence of distant
metastasis. P-values <0.05 were considered as statistical
significant.
3 Results
3.1 Patient and tumor characteristics
Patient and tumor characteristics of 40 stage II colon cancer
patients are listed in Table 1. Twenty-eight tumors were
MSS and 12 MSI. Relapse of tumor occurred in 14 MSS
patients and 2 MSI patients (P=0.05). No significant
differences in age, gender, number of nodes assessed,
differentiation grade, T-stage and other histopathological
variables between patients who relapsed and who did not
were seen (Table 1). Mean follow-up time for all patients
was 73 months (range 2–155). A trend was seen for DFS of
MSI patients being better compared to MSS patients,
although this was not significant (5-year DFS 80% versus
50%, P=0.06) (Fig. 1). Survival time for MSS patients with
Deletion of 4q Predicts Outcome in Stage II CRC 217(n=14) or without (n=14) relapse was 23 months (range 2–
59) versus 104 months (range 5–155), respectively.
3.2 DNA copy numbers aberrations in MSS and MSI stage
II colon cancer patients
CGH profiles of 40 stage II colon cancers patients showed
copy number aberrations consistent with those reported in
literature [7, 8, 10, 35, 36]. The mean fraction of the
genome altered was 15.3% (range 0–44%), and was
significantly higher for MSS tumors (19.4%, range 0–
44%) compared to MSI tumors (5.9%, range 0–18%) (P<
0.001). The amount of losses versus gains was balanced in
the MSS tumors, but MSI tumors showed more gains than
losses; gains 4.8% (0–16.2%) versus losses 1.1% (0–
3.1%). GainsinMSItumorspredominatelyoccurredat8q24.3
(4 out of 12) and 9p21.3 (4 out of 12) and losses at 6p22.1
(4 out of 12), 16p13.2 (5 out of 12) and 17p13.1 (3 out of 12).
For MSS tumors the highest frequency of aberrations (in more
than 12 out of 28 patients) were gains of chromosome
7p22-p11, 7q11, 7q22, whole chromosome 13 and 20
and losses of chromosome 8p23.1-p12, 15q13.3-q26.1,
17p13.2-p11.2and18p11.3-q22.3.DNAcopynumberchanges
of MSI and MSS tumors are summarized in Fig. 2a and b.
3.3 Differences in DNA copy numbers aberrations
between stage II colon cancer patients
with and without relapse
Overall, significant differences were observed between
patients without or with relapse, with 11.2% versus 21.4%
of the genome altered (P=0.005). This was primarily
reflected in the amount of losses which was 10.9% of the
genome for the patients which relapsed versus 3.9% for the
Table 1 Patients and tumor characteristics of stage II colon cancers (N=40)
No Relapse (n=24) Relapse (n=16) P-value
Mean Age (years) (range) 72 (49-91) 73 (54-90) ns
$
Mean number of nodes assessed (range) 8.5 (3-17) 7.7 (1-22) ns
$
Gender






























Yes 10 2 0.05
§
No 14 14
*Right (caecum, ascending colon, transverse colon, hepatic flexure)
# Left ( splenic flexure, descending colon, sigmoid colon)
EMVI = Extramural vascular invasion
Ns = not significant
$ Mann-Whitney U-test;
§Chi-square
218 R.P.M. Brosens et al.Fig. 1 Kaplan-Meier analysis
of disease-free survival for 40
stage II colon cancer patients
stratified by MSI / MSS status.
MSI colon tumors showed a
trend towards better disease-free
survival compared to MSS
patients (P=0.06)
Fig. 2 Percentage of chromo-
somal gains and losses measured
by array CGH in (a) 28 MSS
and (b) 12 MSI stage II colon
cancers patients. X-axis displays
44,000 oligo-nucleotides in ge-
nomic order (chromosomes 1–
22). Y-axis displays percentage
of tumor with gains (>0) or
losses (<0). Boundaries of chro-
mosomes are indicated by black
vertical lines and locations of
centromeres are indicated by
dotted lines
Deletion of 4q Predicts Outcome in Stage II CRC 219patients which remained disease free (P=0.002). The
chromosomal region(s) which significantly differed between
patients with or without relapse were losses on chromosome
4p16.1-p12 (30 Mb), 4q12-q35.2 9 (127 Mb), 5p14 (9 Mb),
5q11.2-q14.2 (21 Mb), 5q32-q34 (0.86 Mb), 15q11.2-q26.1
(21 Mb), 17q21.1 (0.48 Mb), 18q12.1-q12.3 (15 Mb) and
18q21.1-q22.13 (6 Mb). No significant difference was
observed in the amount of gains, 7.3% of the genome altered
for patients who did not relapse versus 10.5% for patients that
did (P=0.11).
Also among the 28 MSS patients, more aberrations were
observed in patients who relapsed (P=0.03), being mainly
losses. Loss of chromosome 4q22.1-4q35.2 (90.5 Mb) was
the most common aberration, being more frequently deleted
in patients with relapse of tumor. Loss of 4q22.1-4q35.2
was seen in 43% to 50% (P=0.01 to P=0.004) of patients
who relapsed, depending on which boundaries for the lost
region were used. An overview of DNA copy number
changes in MSS patient who either relapsed or not, is
presented in Fig. 3. The number of MSI patients was too
small to further stratify and analyze differences between
either or not relapse occurred.
Both OS and DFS were significantly worse for patients
with loss of chromosome 4q22.1-4q35.2 or part of that
region. Considering any loss on chromosome 4q22.1-
4q35.2 predicted worse OS and DFS survival (5-year OS
70% versus 5%, P<0.001; 5-year DFS 75% versus 5%, P<
0.001) (Fig. 4). Cox proportional hazard model demon-
strated that any loss on chromosome 4q22.1-4q35.2 was an
independent prognostic factor for worse DFS (HR=15.4,
P<0.001). Age>72.5 year (HR=6.7, P=0.04) and any
loss on chromosome 4q22.1-4q35.2 (HR=16.9, P<0.001)
were independent prognostic factors for OS.
4 Discussion
A substantial part of stage II colon cancer patients currently
develop distant metastasis after resection of their primary
tumor and subsequently die of their disease. Nevertheless,
Fig. 3 Percentage of chromo-
somal gains and losses measured
by array CGH in 28 MSS stage
II colon cancer patients without
(a) and with (b) relapse of
disease. X-axis displays 44,000
oligo-nucleotides in genomic
order (chromosomes 1–22).
Y-axis displays percentage of
tumor with gains (>0) or losses
(<0). Boundaries of chromo-
somes are indicated by black
vertical lines and the location of
centromeres are indicated by
dotted lines
220 R.P.M. Brosens et al.the American Society of Clinical Oncology (ASCO) [5] and
the National Comprehensive Cancer Network (NCCN) [44]
independently recommended against routine administration
of adjuvant therapy in stage II disease, due to a lack of
evidence for the benefit of survival [5, 14, 17, 24, 45].
Notwithstanding, it has been suggested that subgroups of
stage II patients will benefit from adjuvant therapy. At
present no objective parameters for selecting these patients
are established [10, 28]. Hence, objective and robust
prognostic markers are desirable to select and stratify stage
II colon cancer patients at high risk for relapse. The present
study found in stage II colon cancer patients deletion of
chromosome 4q to be associated with relapse of disease.
This conclusion is consistent with literature [1–3, 11, 12,
19] and suggests that it could be worthwhile further
exploring whether patients with loss of chromosome 4q
should be considered for adjuvant therapy.
Moreover, in the present study significantly more losses
of chromosome 4p, 4q, 5p, 5q, 15q, 17q, and 18q were seen
in tumors of patients who had cancer relapse. This
observation is validated by the results published by Sheffer
et al who linked worse prognosis to a simultaneous deletion
of 4p,15q and 18q in colorectal cancer [32]. Forty percent
(12 of 40) of tumors were MSI and had 5.8% of their
genome altered, which were primarily gains (4.8%). This is
in accordance with results reported by Trautman et al. who
reported 2.3% gain versus 0% loss in 23 MSI and 17.2%
gain versus 19.9% loss in 23 MSS sporadic colon cancers
analyzed by BAC array CGH [35].
When MSS patients were analyzed, only losses in the
region of 4q22.1-35.2 occurred significantly more frequent in
patients who relapsed compared to those who did not. Losses
of 4p, 5p, 5q, 15q, 17q, and 18q were associated but not
significantly related to relapse when only MSS patients were
analyzed. A likely explanation for this could be a limited
sample size and hence lack of power to detect associations
with e.g. 18q loss at a statistically significant level. Loss of
18q as prognostic marker in stage II CRC have been reported
previously based on loss of heterozygosity analysis [21, 25].
As no aberrations on chromosome 4 were seen in MSI
tumors, loss of 4q appears particularly relevant for predicting
relapse in patients with stage II MSS colon tumors.
Numerous studies have analyzed the relation of DNA
copy number changes and clinical outcome in colorectal
cancer patients. In only a small number of studies the
prognostic value of chromosomal aberrations limited to
patients with early stage colon cancer have been analyzed.
In 70 stage I and II MSI and MSS colorectal cancer
patients, loss of chromosome 4p was an independent
prognostic factor, and loss of chromosomes 4 and 14q
were associated with a worse prognosis [2]. This study used
BAC array CGH and reported minimally deleted regions at
4q24-28 and 4q32-35, which is consistent with the findings
in the present study [2]. Additional detailed analysis of this
group of patients using low resolution loss of heterozygosity
(LOH) analysis showed that in particular loss of 4p16, 4q31.1
and 4q33.1 was related to prognosis, further validating our
findings [1]. When chromosomal aberrations were studied
with CGH in stage I-IV colorectal tumors, loss of chromo-
some 4q resulted in shorter survival times [11], loss of 4q32-
34 was associated with metastasis [3] and loss of 4q35 and
4q31.3 correlated with shorter disease-specific survival [19].
A meta-analysis of 31 CGH studies encompassing copy
number profiles of 373 colorectal tumors and 102 liver
metastasis, showed loss of chromosome 4 to be related to
progression from primary tumor to distant metastasis [12].
Loss of chromosome 4q in relation to survival does not seem
to be CRC specific, but has also been reported for other
Fig. 4 Kaplan-Meyer disease-
free survival plot of 28 MSS
stage II colon cancer patients
stratified for any loss of chro-
mosome 4q22.1-q35.2. Stage II
colon tumors with any loss on
chromosome 4q22.1-q35.2
showed worse disease-free sur-
vival than without losses on
4q22.1-q35.2 (P=0.004)
Deletion of 4q Predicts Outcome in Stage II CRC 221epithelial tumors; i.e. bladder [31], head and neck [9],
prostate [26] and breast cancer [33]. Deletion of 4q has also
been associated with micro metastasis in lung cancer [46].
The critical region 4q22.1-35.1 encompasses 90.5 Mb of
chromosomal region with 265 coding genes. The size of the
region thus makes it difficult to pin-point the candidate
tumor suppressor genes or non-coding RNA. Integration of
array CGH and gene expression array or extensive mutation
analysis by next generation sequencing could possibly
further narrow down the number of candidate driver genes.
In summary, loss of chromosome 4q22.1-35.1 may
predict relapse of disease stage II colorectal cancer patients.
Chromosome 4q may thus have important prognostic value
for patient tailored therapy.
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